Natural variability in the disease course of SSc-ILD: implications for treatment

Madelon C. Vonk, Ulrich A. Walker, Elizabeth R. Volkmann, Michael Kreuter, Sindhu R. Johnson, Yannick Allanore

Source: Eur Respir Rev, 30 (159) 200340; 10.1183/16000617.0340-2020
Journal Issue: March
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Madelon C. Vonk, Ulrich A. Walker, Elizabeth R. Volkmann, Michael Kreuter, Sindhu R. Johnson, Yannick Allanore. Natural variability in the disease course of SSc-ILD: implications for treatment. Eur Respir Rev, 30 (159) 200340; 10.1183/16000617.0340-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control
Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium
Year: 2008

Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019

Key recommendations for monitoring disease course of IPF
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: evidence based guidelines and recommendations for clinical management - Results of the joint ATS/ERS/JRS taskforce
Year: 2009

COPD as a lung disease with heterogeneous systemic inflammatory consequences: clinical impact
Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD
Year: 2011

Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009

The natural history of untreated NTM lung disease: a global perspective
Source: International Congress 2017 – Clinical impact of nontuberculous mycobacterial (NTM) disease
Year: 2017

Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg).
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020

Does the HLA-DRB1-genotype influence the course of disease in Danish sarcoidosis patients?
Source: Annual Congress 2013 –Sarcoidosis
Year: 2013

Initial clinical phenotype of COPD: Correlation with the natuaral history of the disease
Source: Annual Congress 2011 - COPD management
Year: 2011

Clinical course of childhood asthma: a role of disease severity
Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children
Year: 2008

Immunodeficiencies in adulthood: lung disease manifestations and treatment options
Source: International Congress 2019 – PG6 Immunodeficiencies in lung diseases
Year: 2019

Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015

Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice
Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies
Year: 2009

The disease model: implications for clinical practice
Source: Eur Respir J, 51 (4) 1800188; 10.1183/13993003.00188-2018
Year: 2018

Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives
Source: Eur Respir J 2005; 26: 984-985
Year: 2005

Mast cells in lung disease: clinical implications
Source: International Congress 2019 – It takes two to tango: translating scientific findings into clinical applications
Year: 2019

PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Source: Eur Respir Rev 2013; 22: 148-152
Year: 2013

Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities
Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options
Year: 2021

Interstitial lung disease: new challenges and evolving phenotypes
Source: Eur Respir Rev 2009; 19: 91-93
Year: 2010